LifeStance Health Group (NASDAQ:LFST - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 7th. Analysts expect LifeStance Health Group to post earnings of ($0.03) per share and revenue of $332.71 million for the quarter.
LifeStance Health Group Stock Up 0.5 %
Shares of LFST stock opened at $6.56 on Wednesday. LifeStance Health Group has a 1 year low of $4.64 and a 1 year high of $8.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. The business's fifty day moving average is $6.94 and its 200-day moving average is $7.30. The stock has a market cap of $2.52 billion, a PE ratio of -25.23 and a beta of 1.30.
Insider Buying and Selling at LifeStance Health Group
In related news, insider Lisa K. Miller sold 18,845 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the sale, the insider now directly owns 339,810 shares in the company, valued at approximately $2,344,689. This trade represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.60% of the company's stock.
Analyst Ratings Changes
Several brokerages have commented on LFST. William Blair reiterated an "outperform" rating on shares of LifeStance Health Group in a research report on Friday, February 28th. KeyCorp initiated coverage on LifeStance Health Group in a research report on Tuesday, April 8th. They set an "overweight" rating and a $9.00 price objective for the company. Finally, Canaccord Genuity Group initiated coverage on LifeStance Health Group in a research note on Thursday, April 3rd. They issued a "buy" rating and a $8.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.30.
View Our Latest Stock Report on LFST
LifeStance Health Group Company Profile
(
Get Free Report)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LifeStance Health Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeStance Health Group wasn't on the list.
While LifeStance Health Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
